trimetazidine / Generic mfg. - LARVOL DELTA

Mechanistic insights into trimetazidine's protection against bladder ischemia-reperfusion injury via mirR-211/CHOP modulation and SIRT1/AMPK/PGC1α-mediated mitochondrial biogenesis. (PubMed, Toxicol Appl Pharmacol) - "TMZ exerts strong antioxidant, anti-inflammatory, anti-apoptotic, and cytoprotective effects in bladder I/R injury via modulation of oxidative stress, ER stress, mitochondrial pathways, and the mirR-211/CHOP axis. These findings suggest that TMZ may represent a promising therapeutic candidate for ischemia-associated bladder dysfunction, providing a mechanistic basis for future translational and clinical investigation."

Journal • Cardiovascular • Inflammation • Reperfusion Injury • Urology • AMPK • CASP3 • IL1B • SIRT1 • TNFA

Efficacy and Prognosis of Blinatumomab As a Bridge Therapy for Hematopoietic Stem Cell Transplantation for B-ALL (ASH 2024) - "MRD of the target genes was quantified using a multiparameter Flow cytometry, and the bridged Hematopoietic stem cell transplantation was performed after 7 days of 28 UG of Blinatumoma treatment, it uses dexamethasone to prevent CRS, Levetiracetam to prevent ICAN, and trimetazidine to nourish the myocardium.Methods : Forty-four patients (22 female, 22 male) , with a median age of 36.5(13-60 years) . With a median follow-up of 11 months, 41 patients had 1-year OS and PFS of 77.9% and 76.9% , respectively, and 10 MRD positive patients had 1-year OS and PFS of 66.4% and 65.6% , respectively, the 1-year OS and PFS of 31 MRD negative patients were 82.4% and 82% , respectively. Nine patients died after transplantation, including 9 from severe infection, 2 from GVHD and 3 from relapse.Result : Bridging transplantation after 7 days of continuous use of Blinatumoma has been shown to improve remission rates and long-term survival in patients with B-ALL, particularly in..."

Clinical • Bone Marrow Transplantation • Cardiovascular • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

Intranasal Liposomal Trimetazidine Nanocarriers Modulate Neuroinflammation and Neurotransmission via the HMGB1/TLR4/NF-κB Pathway in an Experimental Epilepsy Model. (PubMed, Mol Neurobiol) - "These findings demonstrate the potential of intranasal delivery of NTMZ as a novel formulation for managing epilepsy through its improved bioavailability, reduced dose, sustained release, and potent neuroprotective properties. Simultaneously, pharmacological modulation of neuroinflammation and neurotransmitters were observed."

Journal • CNS Disorders • Cognitive Disorders • Epilepsy • Inflammation • Metabolic Disorders • HMGB1 • IL1B • IL6 • TLR4 • TNFA

Early combination therapy with trimetazidine rapidly improves symptoms and quality of life in patients recently diagnosed with stable angina: The COMBINE angina study. (PubMed, Int J Cardiol) - P | "The real-world COMBINE Angina study showed that early initiation of trimetazidine combination therapy can rapidly reduce the burden of stable angina in patients not promptly controlled by a first-line calcium channel blocker or β-blocker."

HEOR • Journal • Cardiovascular • Myocardial Ischemia

Comparative Hepatoprotective Effects of Dapagliflozin and Trimetazidine in Diabetic Rats with Doxorubicin-Induced Liver Injury. (PubMed, Biomedicines) - " Dapagliflozin and trimetazidine each attenuated diabetes- and doxorubicin-related hepatic injury through partly distinct mechanisms, with the combination providing additive but not consistently superior effects. These findings suggest a potential hepatoprotective role for both agents; however, the clinical implications remain uncertain and require confirmation in further mechanistic and translational studies."

Journal • Preclinical • Diabetes • Hepatology • Liver Failure • Metabolic Disorders • Oncology • CASP3 • NFKB1 • TGFB1 • TNFA

Trimetazidine Alleviates Heart Failure after Myocardial Infarction by Promoting PINK1/Parkin-mediated Mitophagy and Suppressing GPX4-Dependent Ferroptosis. (PubMed, Eur J Pharmacol) - "Molecular docking further validated TMZ's potential direct interaction with PINK1. In conclusion, these findings demonstrate that TMZ ameliorates post-MI heart failure by orchestrating mitochondrial quality control through promotion of mitophagy and suppression of GPX4-dependent ferroptosis, offering novel mechanistic insight into its therapeutic potential in the management of ischemic heart disease."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Metabolic Disorders • Myocardial Infarction • GPX4 • MFN1 • SLC7A11

Targeting SIRT5 By Succinylating Hadha Synergizes with Venetoclax in Acute Myeloid Leukemia (ASH 2023) - "One of the mechanisms of action of the combination of venetoclax and azacitidine is to inhibit amino acid metabolism, leading to cell death...Moreover, the combination of trimetazidine (a specific inhibitor of HADHA) with venetoclax demonstrated a preferential reduction in cell proliferation and induction of apoptosis in AML cells... Targeting of SIRT5 in combination with venetoclax treatment results in synergistic cytotoxic effects in AML cells. We hypothesize that SIRT5 desuccinylase activity promotes FAO and reduces intracellular mitochondrial ROS levels by desuccinylating HADHA. Targeting SIRT5 inhibits fatty acid metabolism in AML cells, thereby enhancing the therapeutic effect of venetoclax."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology • BCL2 • SIRT5

Cost-Effectiveness Model of Ranolazine for Treating Chronic Stable Angina Patients From Kingdom of Saudi Arabia Perspective (ISPOR-EU 2025) - "This insight, along with the importance of stratifying outcomes by angina severity and including revascularization impacts, guided the development of a 1-year decision tree model which compared ranolazine+sublingual nitro-glycerine (SNG) against placebo+SNG and trimetazidine+SNG. Trimetazidine was selected as the comparator due to its lower cost, high prevalence (approximately 95%) in Saudi Arabian second-line treatments, and superior safety profile compared to Ivabradine... Ranolazine is a cost-effective treatment compared to placebo and trimetazidine from KSA payor perspective. These findings are vital for optimizing healthcare resource allocation and ensuring patient access amidst rising costs."

Clinical • Cost effectiveness • HEOR • Cardiovascular

"Trimetazidine Protects against Doxorubicin-induced Chemobrain in Rats: Insights into Energy Imbalance and Neuroinflammation". (PubMed, Eur J Pharmacol) - "Notably, the 60 mg/kg dose of TMZ demonstrated superior efficacy. These findings provide a strong rationale for further clinical evaluation of TMZ-DOX combination regimens as a potential strategy to prevent DOX-associated cognitive impairment."

Journal • Preclinical • Alzheimer's Disease • Cardiomyopathy • Cardiovascular • CNS Disorders • Cognitive Disorders • Inflammation • CASP3 • TNFA

The crosstalk between mitochondrial dysfunction and fatty acid metabolism in heart failure: mechanisms and therapeutic strategies. (PubMed, Front Pharmacol) - "In addition, we provide an updated overview of therapeutic strategies, including pharmacological modulators such as SGLT2 inhibitors and trimetazidine, as well as traditional Chinese medicine formulas such as Qiliqiangxin and Qishen granules, which have shown preliminary benefits in clinical studies. Although the proposed vicious cycle remains a working hypothesis requiring further validation, understanding this interplay may help identify novel biomarkers, stratify patients by metabolic phenotype, and guide precision therapies for HF."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

Endothelial Dysfunction in a Patient With Post-COVID-19 Syndrome and Mutation of the MTHFR Gene and Prothrombin II. (PubMed, Cureus) - "The patient initially received prophylactic anticoagulation with apixaban during hospitalization, which was discontinued after discharge. Long-term treatment included low-dose aspirin, folic acid, B-complex vitamins, bisoprolol, and trimetazidine for angina control...This case suggests that patients with platelet hyperreactivity, MTHFR (C677T), and prothrombin factor II (G20210A) mutations may be predisposed to developing ED and coronary microcirculatory impairment following SARS-CoV-2 infection in post-COVID-19 syndrome. We address the use of prophylactic anticoagulants in selected cases such as ours, which, although not specifically recommended by current guidelines (American Society of Hematology), may be considered after an individualized risk-benefit assessment."

Journal • Cardiovascular • Fatigue • Hematological Disorders • Infectious Disease • Inflammation • Metabolic Disorders • Novel Coronavirus Disease • Pain • Pulmonary Disease • Respiratory Diseases • MTHFR

Targeting the PHD2/HIF-1α/HO-1 pathway: A key role of trimetazidine in hypertensive nephropathy. (PubMed, Clin Exp Hypertens) - "These effects were further enhanced by PHD2 knockdown (TMZ + si-PHD2), but reversed by the inhibition of HO-1 or HIF-1α (TMZ + ZnPP, TMZ + KC7F2). TMZ improves HN in mice by modulating the PHD2/HIF-1α/HO-1 pathway."

Journal • Fibrosis • Immunology • Renal Disease • HIF1A • HMOX1

Ophthalmic antioxidant activity of a model antianginal drug using corneal hydrogel formulation: Effect of carboxymethyl starch on physicomechanical behaviour and release/permeation kinetics. (PubMed, Int J Biol Macromol) - "Flexible docking studies demonstrated a stronger binding interaction between TIZ and IL-1β (-5.4 kJ/mol) compared to diclofenac (-4.68 kJ/mol) and dexamethasone (-5.33 kJ/mol). Trimetazidine hydrogel could be used for controlled ophthalmic antioxidant activity after topical application. Presence of CMS improved physicomechanical performance."

Journal • Ophthalmology • IL1B

Reviving the Mitochondria: A Hopeful Horizon in Refractory Heart Failure. (PubMed, Cureus) - "Recent advances in mitochondrial-targeted therapies have opened new possibilities for treating HF at its energetic roots. This editorial explores the pathophysiological role of mitochondria in HF, reviews emerging therapeutic strategies aimed at restoring mitochondrial function, and outlines key challenges that must be addressed to translate these innovations into clinical practice."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

Danggui Buxue decoction activates AMPK/PGC-1α pathway to improve chronic heart failure. (PubMed, J Ethnopharmacol) - "DBD has the potential to counteract heart failure-induced cardiac impairment and preserve myocardial tissue integrity by modulating energy metabolism. This beneficial effect likely stems from DBD's ability to influence the AMPK/PGC-1α signaling pathway, which plays essential role in regulating cellular energy processes."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • NRF1 • SLC2A4

Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation. (PubMed, J Am Heart Assoc) - "Treatment with trimetazidine is associated with a lower risk of incident and recurrent stroke in patients with both ischemic heart disease and AF. These findings will need to be confirmed in randomized controlled trials."

Journal • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Heart Failure • Ischemic stroke • Myocardial Ischemia

Beneficial Effect of Trimetazidine on Streptozotocin Induced Diabetic Nephropathy in Rats by Enhancing Glutathione Status. (PubMed, Mymensingh Med J) - "It may be assumed from this study that trimetazidine has nephroprotective effects because of its special antioxidant effects, which can delay the onset, severity and progression of nephropathy induced by streptozotocin in rats. Therefore, trimetazidine may be extensively studied in human with diabetic nephropathy for confirmation of its nephro-protective effects."

Journal • Preclinical • Diabetic Nephropathy • Nephrology • Renal Disease

Trimetazidine-Profen Hybrid Molecules: Synthesis, Chemical Characterization, and Biological Evaluation of Their Racemates. (PubMed, Pharmaceuticals (Basel)) - " The hybrid trimetazidine-profen compounds synthesized herein, especially compound 3c, demonstrate promising dual antioxidant and anti-inflammatory therapeutic potential. Their stable interaction with serum albumin and balanced physicochemical properties support further development as novel agents for managing ischemic heart disease and associated inflammatory conditions."

Journal • Cardiovascular • Coronary Artery Disease • Heart Failure

Evaluation of the Potential Benefits of Trimetazidine in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial. (PubMed, Pharmaceuticals (Basel)) - " This groundbreaking trial supports the potential of trimetazidine as a promising therapeutic agent for MASLD, indicating substantial improvements in hepatic steatosis, inflammation, and metabolic disturbances. These findings underscore the urgency and importance of further multicenter trials to validate trimetazidine's efficacy as a disease-modifying therapy for MASLD."

Journal • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • CRP • IL6 • TNFA

Contemporary Antianginal Therapy. (PubMed, Am J Cardiovasc Drugs) - "Beta-blockers and calcium channel blockers remain the foundation of symptom management, while nitrates, ranolazine, ivabradine, and trimetazidine may be considered for refractory symptoms. Emerging interventional strategies and stem cell-based interventions show promise for patients with refractory angina who lack further revascularization options. The limited progress in novel pharmacologic development reinforces the need for ongoing research to refine therapeutic strategies for CMD and expand treatment options for patients with treatment-resistant angina."

Journal • Review • Cardiovascular

Adverse analytical finding with trimetazidine after ingesting contaminated melatonin tablets sold in pharmacies… leading to the suspension of the athlete. (PubMed, Clin Chem Lab Med) - No abstract available

Journal

ZFHX3 Knockdown Enhances Metabolic Distress in Atrial Myocytes Through Mitochondrial and Calcium Dysregulation: Mitigation by Trimetazidine. (PubMed, Int J Mol Sci) - "ZFHX3 KD cells exhibited a higher acute response in oxygen consumption after Etomoxir injection, upregulated CD36 and phosphorylated ACC expression, increased glucose uptake and lactate production, reduced PDH activity, and higher levels of PDK4 and LDHA. These findings suggest that ZFHX3 downregulation shifts substrate preference toward fatty acid utilization at the expense of glucose oxidation, contributing to metabolic and mitochondrial calcium dysregulation. TMZ mitigates these effects, highlighting its therapeutic potential in AF associated with ZFHX3 deficiency."

Journal • Atrial Fibrillation • Cardiovascular • Metabolic Disorders • CD36 • LDHA • PDK4 • SCARB1 • ZFHX3

HEARTRIP: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI (clinicaltrials.gov) - P4 | N=681 | Completed | Sponsor: Shenyang Northern Hospital | Recruiting ➔ Completed

Trial completion

Results of a Single-Center Prospective Observational Study: How to Take Care of the Heart of a Cancer Patient. (PubMed, Kardiologiia) - "The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine. Thus, by the final visit, 13.1% of patients had died in the main group while in the comparison group, mortality was almost two times higher and reached 22.7%. Conclusion    The study demonstrated clinical effectiveness of the cardioprotective therapy in cancer patients at high and very high risk of cardiotoxicity. The patients who did not receive the primary drug prevention of cardiovascular toxicity had a statistically significant impairment of the LV systolic function, an increased number of developed complications, and a higher mortality."

Journal • Observational data • Cardiovascular • Oncology • MPO

"The Effect of Trimetazidine on the Clinical Outcome of Acute Ischemic Stroke Patients" (clinicaltrials.gov) - P3 | N=60 | Completed | Sponsor: Ain Shams University | Trial completion date: Dec 2025 ➔ May 2025 | Trial primary completion date: Dec 2025 ➔ Feb 2025 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke